US FDA expand mitral valve repair device indicationMay 8, 2019
The US FDA has expanded indication to MitraClip device to repair a leaky mitral valve without open-heart surgery, Abbott announced.
MitraClip is the first transcatheter mitral valve intervention therapy approved to treat select heart failure patients with clinically significant secondary, or functional, mitral regurgitation (MR).
The MitraClip device repairs MR without open-heart surgery and is delivered to the heart through a small incision in the leg. The device clips portions of the leaflets, or flaps, of the mitral valve together to reduce the backflow of blood, restoring the heart’s ability to pump oxygenated blood more efficiently.